Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of venetoclax + daratumumab + dexamethasone with or without bortezomib in relapsed or refractory multiple myeloma
2023-506110-43-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of venetoclax, daratumumab, dexamethasone and bortezomib in multiple myeloma (MM) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Overall response rate, Very good partial response or better rate and 6 more. Planned start Jan 2018; status: authorised.
02
Drugs
venetoclaxdaratumumabdexamethasonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-506110-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506110-43-00.